Literature DB >> 12009238

Characteristics of long-term survivors of untreated lung cancer.

Jürgen Mattern1, Reet Koomägi, Manfred Volm.   

Abstract

Non-small cell lung cancer (NSCLC) is a malignant tumor with poor prognosis. Although the prognostic variables determining short-term survival have been well described, relatively little attention has been paid to factors associated with long-term survival. In search of these factors we studied the expression of several molecular markers in NSCLC. Only tumor samples of patients with squamous cell carcinomas and stage III tumors with a postoperative survival of at least 5 years and those of patients who died within 2 years after resection were selected for this study. The expression of several parameters including oncogene and suppressor gene products, proliferative, apoptotic, angiogenic and resistance-related factors were investigated and the differences in these two extreme populations were determined by the Wilcoxon rank sum test. Factors involved in proliferation (ras, fos, erbB-1, jun, cyclin A) were downregulated whereas factors involved in apoptosis (p53, bcl-2, CD95) were upregulated in the long survival group. Direct measurement of parameters of proliferation (cell cycle analysis by flow cytometry, PCNA index) revealed a lower proliferative activity in tumors of the long survivors compared to short survivors. In conclusion, tumors of the long survival group are characterized by a downregulation of factors involved in proliferation and an upregulation of factors involved in apoptosis. These tumors may grow more slowly and this may influence long-term survival of patients with NSCLC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12009238     DOI: 10.1016/s0169-5002(02)00010-7

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  5 in total

Review 1.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

2.  Differences in protein expression and gene amplification of cyclins between colon and rectal adenocarcinomas.

Authors:  Rolf Aamodt; Kristin Jonsdottir; Solveig Norheim Andersen; Johan Bondi; Geir Bukholm; Ida R K Bukholm
Journal:  Gastroenterol Res Pract       Date:  2009-12-15       Impact factor: 2.260

3.  A dominant-negative c-jun mutant inhibits lung carcinogenesis in mice.

Authors:  Jay W Tichelaar; Ying Yan; Qing Tan; Yian Wang; Richard D Estensen; Matthew R Young; Nancy H Colburn; Hulian Yin; Colleen Goodin; Marshall W Anderson; Ming You
Journal:  Cancer Prev Res (Phila)       Date:  2010-08-17

4.  A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.

Authors:  Yan Lu; William Lemon; Peng-Yuan Liu; Yijun Yi; Carl Morrison; Ping Yang; Zhifu Sun; Janos Szoke; William L Gerald; Mark Watson; Ramaswamy Govindan; Ming You
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

5.  Integrated analysis reveals five potential ceRNA biomarkers in human lung adenocarcinoma.

Authors:  Yu Liu; Deyao Xie; Zhifeng He; Liangcheng Zheng
Journal:  PeerJ       Date:  2019-04-29       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.